JP2024508780A5 - - Google Patents
Info
- Publication number
- JP2024508780A5 JP2024508780A5 JP2023550150A JP2023550150A JP2024508780A5 JP 2024508780 A5 JP2024508780 A5 JP 2024508780A5 JP 2023550150 A JP2023550150 A JP 2023550150A JP 2023550150 A JP2023550150 A JP 2023550150A JP 2024508780 A5 JP2024508780 A5 JP 2024508780A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- item
- alkyl
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163151060P | 2021-02-18 | 2021-02-18 | |
| US63/151,060 | 2021-02-18 | ||
| PCT/IB2022/000074 WO2022175749A1 (en) | 2021-02-18 | 2022-02-18 | Compositions for conjugating oligonucleotides and carbohydrates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508780A JP2024508780A (ja) | 2024-02-28 |
| JP2024508780A5 true JP2024508780A5 (enExample) | 2025-02-26 |
Family
ID=81386899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550150A Pending JP2024508780A (ja) | 2021-02-18 | 2022-02-18 | オリゴヌクレオチドおよび炭水化物をコンジュゲートするための組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250034561A1 (enExample) |
| EP (1) | EP4294449A1 (enExample) |
| JP (1) | JP2024508780A (enExample) |
| CN (1) | CN117222434A (enExample) |
| WO (1) | WO2022175749A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116444589B (zh) * | 2023-06-15 | 2023-09-19 | 北京悦康科创医药科技股份有限公司 | 新型GalNAc化合物及其硫代寡核苷酸缀合物和偶联方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3889261A1 (en) | 2007-08-27 | 2021-10-06 | 1Globe Health Institute LLC | Compositions of asymmetric interfering rna and uses thereof |
| DK2992098T3 (da) * | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| WO2018185253A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Ligand modified double-stranded nucleic acids |
| WO2020123410A1 (en) * | 2018-12-10 | 2020-06-18 | Amgen Inc. | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF |
| CA3132170A1 (en) * | 2019-04-18 | 2020-10-22 | Michael BIERMER | Combination therapy for treating hepatitis b virus infection |
| EP4126967A1 (en) * | 2020-03-23 | 2023-02-08 | Amgen Inc. | Monoclonal antibodies to chemically-modified nucleic acids and uses thereof |
| AU2021373780A1 (en) * | 2020-11-05 | 2023-06-08 | Amgen Inc. | METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS |
| WO2022152869A1 (en) * | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
-
2022
- 2022-02-18 EP EP22719012.1A patent/EP4294449A1/en active Pending
- 2022-02-18 WO PCT/IB2022/000074 patent/WO2022175749A1/en not_active Ceased
- 2022-02-18 CN CN202280015973.5A patent/CN117222434A/zh active Pending
- 2022-02-18 US US18/277,846 patent/US20250034561A1/en active Pending
- 2022-02-18 JP JP2023550150A patent/JP2024508780A/ja active Pending